These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Allopurinol use during pediatric acute lymphoblastic leukemia maintenance therapy safely corrects skewed 6-mercaptopurine metabolism, improving inadequate myelosuppression and reducing gastrointestinal toxicity. Cohen G; Cooper S; Sison EA; Annesley C; Bhuiyan M; Brown P Pediatr Blood Cancer; 2020 Nov; 67(11):e28360. PubMed ID: 32909665 [TBL] [Abstract][Full Text] [Related]
5. Effects of allopurinol on 6-mercaptopurine metabolism in unselected patients with pediatric acute lymphoblastic leukemia: a prospective phase II study. Källström J; Niinimäki R; Fredlund J; Vogt H; Korhonen L; Castor A; Palle J; Harila A; Borssén M; Abrahamsson J; Ek T Haematologica; 2024 Sep; 109(9):2846-2853. PubMed ID: 38356449 [TBL] [Abstract][Full Text] [Related]
6. Allopurinol to Prevent Mercaptopurine Adverse Effects in Children and Young Adults With Acute Lymphoblastic Leukemia. Kamojjala R; Bostrom B J Pediatr Hematol Oncol; 2021 Apr; 43(3):95-100. PubMed ID: 33750748 [TBL] [Abstract][Full Text] [Related]
7. Quantification of Thiopurine Nucleotides in Erythrocytes and Clinical Application to Pediatric Acute Lymphoblastic Leukemia. Moon SY; Lim JH; Kim EH; Nam Y; Yu KS; Hong KT; Choi JY; Hong CR; Kim H; Kang HJ; Shin HY; Lee K; Song J; Lee SY; Song SH Ther Drug Monit; 2019 Feb; 41(1):75-85. PubMed ID: 30507626 [TBL] [Abstract][Full Text] [Related]
8. Assessment on the use of allopurinol to improve safety and efficacy of mercaptopurine in pediatric patients with Acute Lymphoblastic Leukemia and Lymphoma during maintenance therapy. Barone T; Dandekar S; McKeone D; Mulieri K Cancer Rep (Hoboken); 2024 Feb; 7(2):e1987. PubMed ID: 38351548 [TBL] [Abstract][Full Text] [Related]
9. Possible implication of thiopurine S-methyltransferase in occurrence of infectious episodes during maintenance therapy for childhood lymphoblastic leukemia with mercaptopurine. Dervieux T; Médard Y; Verpillat P; Guigonis V; Duval M; Lescoeur B; Suciu S; Vilmer E; Jacqz-Aigrain E Leukemia; 2001 Nov; 15(11):1706-12. PubMed ID: 11681411 [TBL] [Abstract][Full Text] [Related]
10. Thiopurine methyltransferase genotype-phenotype discordance and thiopurine active metabolite formation in childhood acute lymphoblastic leukaemia. Lennard L; Cartwright CS; Wade R; Richards SM; Vora A Br J Clin Pharmacol; 2013 Jul; 76(1):125-36. PubMed ID: 23252716 [TBL] [Abstract][Full Text] [Related]
11. Allopurinol Use During Maintenance Therapy for Acute Lymphoblastic Leukemia Avoids Mercaptopurine-related Hepatotoxicity. Giamanco NM; Cunningham BS; Klein LS; Parekh DS; Warwick AB; Lieuw K J Pediatr Hematol Oncol; 2016 Mar; 38(2):147-51. PubMed ID: 26808368 [TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of 6-Thioguanine and 6-Mercaptopurine Combination Maintenance Therapy of Childhood ALL: Hypothesis and Case Report. Nielsen SN; Frandsen TL; Nersting J; Hjalgrim LL; Schmiegelow K J Pediatr Hematol Oncol; 2015 Apr; 37(3):e206-9. PubMed ID: 25171455 [TBL] [Abstract][Full Text] [Related]
13. Altered mercaptopurine metabolism, toxic effects, and dosage requirement in a thiopurine methyltransferase-deficient child with acute lymphocytic leukemia. Evans WE; Horner M; Chu YQ; Kalwinsky D; Roberts WM J Pediatr; 1991 Dec; 119(6):985-9. PubMed ID: 1960624 [TBL] [Abstract][Full Text] [Related]
14. Allopurinol safely and effectively optimizes tioguanine metabolites in inflammatory bowel disease patients not responding to azathioprine and mercaptopurine. Sparrow MP; Hande SA; Friedman S; Lim WC; Reddy SI; Cao D; Hanauer SB Aliment Pharmacol Ther; 2005 Sep; 22(5):441-6. PubMed ID: 16128682 [TBL] [Abstract][Full Text] [Related]
15. Prevention of mercaptopurine-induced hypoglycemia using allopurinol to reduce methylated thiopurine metabolites. Miller MB; Brackett J; Schafer ES; Rau RE Pediatr Blood Cancer; 2019 Apr; 66(4):e27577. PubMed ID: 30548777 [TBL] [Abstract][Full Text] [Related]
16. Dynamics of leucocyte DNA thioguanine nucleotide levels during maintenance therapy of childhood acute lymphoblastic leukemia. Larsen RH; Hjalgrim LL; Degn M; Nersting J; Als-Nielsen B; Grell K; Schmiegelow K Cancer Chemother Pharmacol; 2021 Jul; 88(1):53-60. PubMed ID: 33754188 [TBL] [Abstract][Full Text] [Related]
17. Key factors associated with 6-thioguanine and 6-methylmercaptopurine nucleotide concentrations in children treated by thiopurine for acute leukaemia and inflammatory bowel disease. de Beaumais TA; Lorrain S; Mamhoudi N; Simonin M; Martinez Vinson C; Medard Y; Petit A; Jacqz-Aigrain E Br J Clin Pharmacol; 2024 Jan; 90(1):209-219. PubMed ID: 37621013 [TBL] [Abstract][Full Text] [Related]
18. Metabolites of mercaptopurine in red blood cells: a relationship between 6-thioguanine nucleotides and 6-methylmercaptopurine metabolite concentrations in children with lymphoblastic leukemia. Chrzanowska M; Kolecki P; Duczmal-Cichocka B; Fiet J Eur J Pharm Sci; 1999 Aug; 8(4):329-34. PubMed ID: 10425383 [TBL] [Abstract][Full Text] [Related]
19. Maintenance therapy for acute lymphoblastic leukemia: basic science and clinical translations. Toksvang LN; Lee SHR; Yang JJ; Schmiegelow K Leukemia; 2022 Jul; 36(7):1749-1758. PubMed ID: 35654820 [TBL] [Abstract][Full Text] [Related]
20. Skin Toxicity Due to Mercaptopurine in Maintenance Therapy Among Children With Acute Lymphoblastic Leukemia. Higgerson K; Flatt T J Pediatr Hematol Oncol; 2023 May; 45(4):e514-e517. PubMed ID: 37027323 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]